Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021. (1st June 2022)

• Record Type: Journal Article
• Authors: Bo, Chunrui; Wang, Tianqi; Hou, Chengbei; Han, Jinming; Chen, Lixia; Zhang, Huixue; Wang, Lihua; Li, Hongyan
• Is Part Of: CNS neuroscience & therapeutics. Volume 28:Number 8(2022)
• Page Start: 1229
• Page End: 1239
• Publication Date: 2022-06-01
• Subjects: drug clinical trials -- ischemic stroke -- mainland China; Neuropharmacology -- Periodicals; Central nervous system -- Diseases -- Effect of drugs on -- Periodicals; 612.8
• DOI: 10.1111/cns.13867
• Languages: English
• ISSNs: 1755-5930

Abstract

Abstract: Background: To assess the temporal changes in the characteristics of ischemic stroke drug clinical trials conducted in mainland China in 2005–2021. Methods: A statistical analysis of registered clinical trials on ischemic stroke was performed using the platform of the Center for Drug Evaluation of China National Medical Products Administration, the Chinese Clinical Trial Registry, and ClinicalTrials.gov websites. Results: From January 1, 2005 to August 1, 2021, a total of 384 registered drug clinical trials on ischemic stroke were identified in mainland China. Over time, the number of trials gradually increased each year, with a significant growth in 2014, from 16 in 2013 to 42 in 2014. Phase IV trials (31.8%) accounted for the majority, followed by phase II (16.4%), phase I (10.9%), and phase III (8.6%). In terms of sponsorship, the proportion of investigator‐initiated trials (IITs) (60.7%) was higher than industry‐sponsored trials (ISTs) (39.3%). Additionally, trials involving traditional Chinese medicines (TCMs) (36.2%) accounted for the largest proportion, followed by trials involving antithrombotic therapy (19.5%) and cerebral protection agents (16.7%). Furthermore, over the past 17 years, the number of leading drug clinical trial units for ischemic stroke in mainland China has continuously increased. The leading principal units from Beijing, Shanghai, Guangdong, Jiangsu, and Liaoning accounted for the majority of the trials (67.4%). Conclusion: In the past 17 years, great progress has been made in the research and development (R&D) of drugs and clinical trials for ischemic stroke in mainland China. The most extensive progress was observed in TCMs, antithrombotic therapy, and cerebral protection agents. More clinical trials are needed to confirm whether the newly developed drugs can improve the clinical efficacy of ischemic stroke. Simultaneously, more pharmaceutical R&D efforts of innovative drugs are warranted. Abstract : In the past 17 years, great progress has been made in the research and development of drugs and clinical trials for ischemic stroke in mainland China. Phase IV trials showed the greatest growth, with an average annual growth rate of 27.8%. The most extensive progress was observed in TCMs, antithrombotic therapy, and cerebral protection agents. This is the first study to depict the evolution of acute ischemic stroke drug clinical trials in mainland China in 2005–2021.